Kestel Selin, Göçün Feriha Pınar Uyar, Öğüt Betül, Erdem Özlem
Department of Pathology, Faculty of Medicine, Gazi University, Ankara, Turkey.
J Pathol Transl Med. 2022 Jul;56(4):187-198. doi: 10.4132/jptm.2022.03.10. Epub 2022 May 3.
We aimed to determine the effect of clinicopathologic features on overall survival among Caucasian ocular melanoma patients in the Central Anatolia region of Turkey.
This single-center study included conjunctival (n = 12) and uveal (n = 19) melanoma patients diagnosed between January 2008 and March 2020. Clinicopathologic features and outcomes were reviewed retrospectively. Five cases were tested for BRAF V600 mutations with real-time polymerase chain reaction, and one case was tested with nextgeneration sequencing. Survival was calculated using the Kaplan-Meier method.
Thirty-one patients had a mean initial age of 58.32 years (median, 61 years; range 25 to 78 years). There were 13 male and 18 female patients. The median follow-up time was 43.5 months (range, 6 to 155 months) for conjunctival melanoma and 35 months (range, 8 to 151 months) for uveal melanoma. When this study ended, eight of the 12 conjunctival melanoma patients (66.7%) and nine of the 19 uveal melanoma patients (47.4%) had died. The presence of tumor-infiltrating lymphocytes was related to improved overall survival in conjunctival melanoma (p = .014), whereas the presence of ulceration (p = .030), lymphovascular invasion (p = .051), tumor in the left eye (p = .012), tumor thickness of > 2 mm (p = .012), and mitotic count of >1/mm² (p = .012) reduced the overall survival in conjunctival melanoma. Uveal melanoma tumors with the largest diameter of 9.1-15 mm led to the lowest overall survival among subgroups (p = .035). Involvement of the conjunctiva (p=.005) and lens (p = .003) diminished overall survival in uveal melanoma. BRAF V600 mutation was present in one case of conjunctival melanoma, GNAQ R183Q mutation was present in one case of uveal melanoma. Patients with uveal melanoma presented with an advanced pathological tumor stage compared to those with conjunctival melanoma (p = .019).
This study confirmed the presence of tumor-infiltrating lymphocytes as a favorable factor in conjunctival melanoma and conjunctival and lens involvement as unfavorable prognostic factors in uveal melanoma for overall survival, respectively.
我们旨在确定临床病理特征对土耳其安纳托利亚中部地区白种人眼黑色素瘤患者总生存期的影响。
这项单中心研究纳入了2008年1月至2020年3月期间诊断的结膜黑色素瘤患者(n = 12)和葡萄膜黑色素瘤患者(n = 19)。对临床病理特征和结局进行回顾性分析。5例患者采用实时聚合酶链反应检测BRAF V600突变,1例患者采用二代测序检测。采用Kaplan-Meier法计算生存率。
31例患者的平均初始年龄为58.32岁(中位数为61岁;范围为25至78岁)。男性患者13例,女性患者18例。结膜黑色素瘤的中位随访时间为43.5个月(范围为6至155个月),葡萄膜黑色素瘤的中位随访时间为35个月(范围为8至151个月)。在本研究结束时,12例结膜黑色素瘤患者中有8例(66.7%)死亡,19例葡萄膜黑色素瘤患者中有9例(47.4%)死亡。肿瘤浸润淋巴细胞的存在与结膜黑色素瘤患者总生存期的改善相关(p = .014),而溃疡的存在(p = .030)、淋巴管浸润(p = .051)、左眼肿瘤(p = .012)、肿瘤厚度>2 mm(p = .012)和有丝分裂计数>1/mm²(p = .012)均降低了结膜黑色素瘤患者的总生存期。最大直径为9.1 - 15 mm的葡萄膜黑色素瘤肿瘤在各亚组中导致的总生存期最低(p = .035)。结膜受累(p = .005)和晶状体受累(p = .003)降低了葡萄膜黑色素瘤患者的总生存期。1例结膜黑色素瘤患者存在BRAF V600突变,1例葡萄膜黑色素瘤患者存在GNAQ R183Q突变。与结膜黑色素瘤患者相比,葡萄膜黑色素瘤患者的病理肿瘤分期更晚(p = .019)。
本研究证实肿瘤浸润淋巴细胞的存在是结膜黑色素瘤总生存期的有利因素,而结膜和晶状体受累分别是葡萄膜黑色素瘤总生存期的不良预后因素。